Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial.

Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology. 2007 Jan; 132(1):52-65.

View in: PubMed

subject areas

Adalimumab
Adolescent
Adult
Aged
Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Antirheumatic Agents
Crohn Disease
Digestive System Fistula
Female
Humans
Male
Middle Aged
Placebos
Remission Induction
Severity of Illness Index
Treatment Outcome

authors with profiles

Stephen B. Hanauer